Credulity of exploratory trials for cerebral cavernous malformations

Affiliations

¹ Neurovascular Surgery Program and the CCM Center of Excellence, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, IL 60637, USA.
² Neurovascular Surgery Program and the CCM Center of Excellence, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, IL 60637, USA. Electronic address: iawad@bsd.uchicago.edu.

Comment

Robert Shenkar et al. Lancet Neurol. 2023 Jan.

. 2023 Jan;22(1):2-3.

doi: 10.1016/S1474-4422(22)00440-9. Epub 2022 Nov 17.

¹ Neurovascular Surgery Program and the CCM Center of Excellence, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, IL 60637, USA.
² Neurovascular Surgery Program and the CCM Center of Excellence, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, IL 60637, USA. Electronic address: iawad@bsd.uchicago.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators. Lanfranconi S, et al. Lancet Neurol. 2023 Jan;22(1):35-44. doi: 10.1016/S1474-4422(22)00409-4. Epub 2022 Nov 17. Lancet Neurol. 2023. PMID: 36403580 Clinical Trial.